Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia

• Conditions: Hypertension; Dyslipidemias

• Registration Number: NCT03009721
• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Brief Summary

The purpose of this study is to investigate the effectiveness and safety of Olostar Tab in patients with essential hypertension and dyslipidemia

Detailed Description

Not available

Study Timeline

• Study Start: 2016-08
• Status Verified: 2017-01
• Study First Submitted: 2017-01-02
• Study First Submitted QC: 2017-01-03
• Last Update Submitted: 2017-01-03
• Study First Posted: 2017-01-04
• Last Update Posted: 2017-01-04
• Primary Completion: 2018-06
• Study Completion: 2018-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 9707

Inclusion Criteria

• Male or female ≥ 19
• Patients have record of blood pressure (SBP/DBP) and LDL-C after prescription of Olostar Tab.

Exclusion Criteria

• Patients that have participated clinical trials or PMS with Olostar Tab.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Percent change from baseline in blood pressure (SBP/DBP)	At 8 Weeks
Percent change from baseline in LDL-Cholesterol (LDL-C)	At 8 Weeks

Trial Locations

Locations (1)

Dongguk Ilsan University Hospital; 🇰🇷 Ilsan, Korea, Republic of